Please login to the form below
Mersana appoints Anna Protopapas as president and CEO
Joins from Millenium Pharmaceuticals
Mersana Therapeutics has named Anna Protopapas as president and CEO.
Protopapas joins the firm, which engineers antibody-drug conjugates (ADCs), from Takeda subsidiary Millennium Pharmaceuticals, where she held the same role.
Commenting on her new role, Protopapas said: “ADCs are a proven approach to cancer with two drugs on the market and over 30 in the clinic. Mersana's Fleximer-ADCs are a best-in-class approach, which overcomes the limitations of other ADC technologies.
“I am very encouraged by the results to date and look forward to working alongside the team at Mersana to translate the technology into important therapies for patients.”
Protopapas has expansive strategic leadership experience, with a demonstrated track record in the biopharma industry. Amongst her time in the sector, Protopapas has served as a member of the executive committee of Takeda, led Takeda's oncology business during her time at Millennium Pharmaceuticals and also held the role of executive VP of global business development.
Protopapas will additionally join Mersana's board of directors.
Share
Related Hub content
- Bluedog is bursting with new creative and digital talent
- Vivid welcomes magical new talent to the team
- Lucid Group announces the appointment of new CFO
- Isabella Dabby promoted to Strategic Planner
- Lucid demonstrates continual investment in its central services with the appointment of its new Head of Talent, Resourcing and HR projects
Featured jobs
- Publications Director, Medical Communications agency, Cambridge
-
Competitive Salary
- Account Director, Healthcare Communications
-
Salary TBC
- Publications Director, Medical Communications agency, Home Based...
-
Competitive Salary
- Client Partner, Healthcare Brand Communications, London
-
Highly competitive package
- Publications Director, Medical Communications agency, Oxford
-
Competitive Salary
Subscribe to our email news alerts
- NICE unveils long-awaited review of methodologies
- Boris Johnson is new PM – but opposition to his Brexit plans mount
- Vertex files cystic fibrosis triple therapy with FDA
- Acadia’s drive to extend use of Nuplazid hits a wall
- Tactful screening & participant sensitivity
- Intec sounds a sad note as Accordion Parkinson’s trial fails
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- Tactful screening & participant sensitivity
- Screening participants can involve asking personal questions that could be perceived as intrusive. Here CMR explores the implications of such lines of questioning....
- Precision paediatrics: Treating patients with CAR-T
- Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
- What does it mean to be an agile organisation
- We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Quick links
Infographics
